VibroFect is revolutionizing nucleic acid delivery through a patented benchtop device that generates controlled, high-frequency oscillatory motion to create highly efficient, non-toxic nanoparticles in just 10 seconds. This breakthrough addresses critical barriers to developing advanced gene therapies for previously untreatable neurological disorders, including ALS, spinal muscular atrophy, and neurodegenerative diseases. Our comprehensive reagent portfolio includes three specialized formulations: ViALL for DNA-based gene therapy applications, ViRNA for RNA therapeutics and mRNA vaccine development, and viPRO for recombinant protein production in biopharmaceutical manufacturing. This complete solution achieves >90% transfection efficiency with <10% cytotoxicity across multiple cell lines, including hard-to-transfect primary cells, delivering superior performance compared to existing technologies like LipofectamineTM and jetPEI® with 3x better biocompatibility and 90x faster preparation time. Vectorialis targets the rapidly growing transfection market ($2.2B in 2024, projected $3.5B by 2030) and the recombinant protein therapeutics market (estimated $300B globally), addressing critical efficiency and manufacturing bottlenecks. The platform supports the entire spectrum of genetic medicine development, from basic research applications to advanced therapeutic manufacturing, including CRISPR/Cas gene editing, personalized CAR-T cell therapies, mRNA vaccine production, and industrial-scale recombinant protein manufacturing. This innovation directly accelerates the translation of genetic medicines from laboratory to clinic by eliminating operator variability and reducing development timelines. By democratizing access to efficient transfection technology across DNA, RNA, and protein production applications, VibroFect enables breakthrough discoveries in gene therapy and advances treatments for rare genetic diseases, cancer immunotherapies, and neurological conditions. Vectorialis is ready for commercial partnerships and seeking strategic collaborations to accelerate genetic medicine breakthroughs.
